<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907113</url>
  </required_header>
  <id_info>
    <org_study_id>1245.12</org_study_id>
    <secondary_id>2008-006086-86</secondary_id>
    <nct_id>NCT01907113</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase 1 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Assessment of the effect of normal and impaired kidney function on the pharmacokinetics,
      pharmacodynamics and safety of BI 10773
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)</measure>
    <time_frame>1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Concentration of the Analyte in Plasma)</measure>
    <time_frame>1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Maximum concentration of Empagliflozin in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration of the Analyte in Plasma</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life and Mean Residence Time of the Analyte in Plasma</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant in Plasma</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Terminal rate constant in plasma (Lz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of the Analyte in the Plasma After Extravascular Administration</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Apparent clearance of the analyte in the plasma after extravascular administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase Lz</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Apparent volume of distribution during the terminal phase Lz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)</measure>
    <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration</time_frame>
    <description>Amount of analyte that is eliminated in urine over the time interval 0-96 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)</measure>
    <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration</time_frame>
    <description>Fraction of analyte excreted unchanged in urine from time point 0-96 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance of the Analyte in Plasma After Extravascular Administration</measure>
    <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration</time_frame>
    <description>Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)</measure>
    <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
    <description>Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Protein Binding</measure>
    <time_frame>1 h before drug administration and 1:30 and 3:00 h after drug administration</time_frame>
    <description>Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Urinary Glucose Excretion (UGE)</measure>
    <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)</time_frame>
    <description>Change from baseline in total urinary glucose excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements</measure>
    <time_frame>Drug administration until end-of-study-examination, 5 days</time_frame>
    <description>Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tolerability by Investigator</measure>
    <time_frame>Drug administration until end-of-study-examination, 5 days</time_frame>
    <description>Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 / Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration (type 2 diabetes and mild renal impairment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 / Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration (type 2 diabetes and moderate renal impairment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 / Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration (severe renal impairment 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 / Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration (kidney failure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 / Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration (type 2 diabetes and normal renal function)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>oral administration</description>
    <arm_group_label>BI 10773 / Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>oral administration</description>
    <arm_group_label>BI 10773 / Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>oral administration</description>
    <arm_group_label>BI 10773 / Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>oral administration</description>
    <arm_group_label>BI 10773 / Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>oral administration</description>
    <arm_group_label>BI 10773 / Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female subjects with type 2 diabetes

          2. Renally impaired male or female subjects

          3. Age 18 - 75 years

          4. BMI 18 - 34 kg/m2, at least 45 kg for females (Body Mass Index)

          5. Signed and dated written informed consent

        Exclusion criteria:

          1. Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders as judged by the investigator.

          2. Relevant gastrointestinal tract surgery

          3. Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric
             disorders or relevant neurological disorders

          4. History of relevant orthostatic hypotension, fainting spells or blackouts; systolic
             blood pressure &lt; 100 or &gt; 160 mm Hg, diastolic blood pressure &lt; 60 or &gt; 100 mm Hg,
             pulse rate &lt; 50 or &gt; 100 1/min

          5. Chronic or relevant acute infections

          6. History of allergy/hypersensitivity (including drug allergies) that are deemed
             relevant to the trial as judged by the investigator

          7. Use within 10 days prior to administration or during the trial of drugs which might
             reasonably influence the results of the trial based on the knowledge at the time of
             protocol preparation. Co medication known to inhibit or induce P-glycoprotein or CYP3A
             is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g.

               -  protease inhibitors, (e.g. ritonavir, lopinavir nelfinavir)

               -  azole antimycotics, (itraconazole, ketoconazole, miconazole)

               -  macrolid antibiotics, (clarithromycin, erythromycin)

               -  amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone,
                  verapamil, tacrolimus, quinidine, reserpine, cyclosporine A Inducers of P-gp or
                  CYP3A are e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, ri-fampin, St.
                  John's wort, troglitazone. In dubious cases, a case by case decision will be made
                  after consultation with the sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.12.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.12.2 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>July 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2014</results_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted in two trial centres as an open-label, parallel group design with one treatment period.
The trial was performed in 40 male and female patients who were assigned to five treatment groups according to their creatinine clearance.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Renal Function</title>
          <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="P2">
          <title>Mild Renal Impairment</title>
          <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="P3">
          <title>Moderate Renal Impairment</title>
          <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="P4">
          <title>Severe Renal Impairment</title>
          <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="P5">
          <title>Kidney Failure</title>
          <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The treated set included all patients who were dispensed study medication and were documented to have at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Normal Renal Function</title>
          <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="B2">
          <title>Mild Renal Impairment</title>
          <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="B3">
          <title>Moderate Renal Impairment</title>
          <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="B4">
          <title>Severe Renal Impairment</title>
          <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="B5">
          <title>Kidney Failure</title>
          <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="11.7"/>
                    <measurement group_id="B2" value="60.0" spread="8.8"/>
                    <measurement group_id="B3" value="63.1" spread="9.5"/>
                    <measurement group_id="B4" value="56.0" spread="12.9"/>
                    <measurement group_id="B5" value="45.8" spread="12.0"/>
                    <measurement group_id="B6" value="55.8" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)</title>
        <description>Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.</description>
        <time_frame>1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>The PK analysis set (PKS) included all evaluable patients in the treated set who provided at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)</title>
          <description>Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.</description>
          <population>The PK analysis set (PKS) included all evaluable patients in the treated set who provided at least one observation for at least one primary (PK) endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10500" spread="17.6"/>
                    <measurement group_id="O2" value="12400" spread="21.6"/>
                    <measurement group_id="O3" value="12600" spread="27.1"/>
                    <measurement group_id="O4" value="17500" spread="18.9"/>
                    <measurement group_id="O5" value="15600" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as mild renal function divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>118.24</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.17</ci_lower_limit>
            <ci_upper_limit>145.38</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as moderate renal function divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>119.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.25</ci_lower_limit>
            <ci_upper_limit>149.47</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as severe renal function divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>166.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>134.44</ci_lower_limit>
            <ci_upper_limit>205.68</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as kidney failure divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>148.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>119.89</ci_lower_limit>
            <ci_upper_limit>183.42</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Concentration of the Analyte in Plasma)</title>
        <description>Maximum concentration of Empagliflozin in plasma</description>
        <time_frame>1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Concentration of the Analyte in Plasma)</title>
          <description>Maximum concentration of Empagliflozin in plasma</description>
          <population>PKS</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="24.1"/>
                    <measurement group_id="O2" value="1430" spread="33.1"/>
                    <measurement group_id="O3" value="1230" spread="30.9"/>
                    <measurement group_id="O4" value="1450" spread="33.0"/>
                    <measurement group_id="O5" value="1250" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as mild renal function divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>118.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.62</ci_lower_limit>
            <ci_upper_limit>150.84</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as moderate renal function divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.33</ci_lower_limit>
            <ci_upper_limit>131.85</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as severe renal function divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>120.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.42</ci_lower_limit>
            <ci_upper_limit>154.25</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as kidney failure divided by normal renal function</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>103.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.18</ci_lower_limit>
            <ci_upper_limit>132.61</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric Coefficient of Variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration of the Analyte in Plasma</title>
        <description>Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration of the Analyte in Plasma</title>
          <description>Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)</description>
          <population>PKS</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.67" upper_limit="4.00"/>
                    <measurement group_id="O5" value="2.50" lower_limit="1.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life and Mean Residence Time of the Analyte in Plasma</title>
        <description>Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life and Mean Residence Time of the Analyte in Plasma</title>
          <description>Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body</description>
          <population>PKS</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Terminal half-life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="57.4"/>
                    <measurement group_id="O2" value="19.3" spread="81.6"/>
                    <measurement group_id="O3" value="19.5" spread="63.9"/>
                    <measurement group_id="O4" value="22.5" spread="74.3"/>
                    <measurement group_id="O5" value="18.5" spread="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean residence time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="37.4"/>
                    <measurement group_id="O2" value="15.7" spread="44.6"/>
                    <measurement group_id="O3" value="18.4" spread="52.7"/>
                    <measurement group_id="O4" value="22.2" spread="57.6"/>
                    <measurement group_id="O5" value="19.8" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant in Plasma</title>
        <description>Terminal rate constant in plasma (Lz)</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant in Plasma</title>
          <description>Terminal rate constant in plasma (Lz)</description>
          <population>PKS</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0398" spread="57.4"/>
                    <measurement group_id="O2" value="0.0360" spread="81.6"/>
                    <measurement group_id="O3" value="0.0355" spread="63.9"/>
                    <measurement group_id="O4" value="0.0308" spread="74.3"/>
                    <measurement group_id="O5" value="0.0375" spread="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance of the Analyte in the Plasma After Extravascular Administration</title>
        <description>Apparent clearance of the analyte in the plasma after extravascular administration</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of the Analyte in the Plasma After Extravascular Administration</title>
          <description>Apparent clearance of the analyte in the plasma after extravascular administration</description>
          <population>PKS</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="17.6"/>
                    <measurement group_id="O2" value="149" spread="21.6"/>
                    <measurement group_id="O3" value="147" spread="27.1"/>
                    <measurement group_id="O4" value="106" spread="18.9"/>
                    <measurement group_id="O5" value="119" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase Lz</title>
        <description>Apparent volume of distribution during the terminal phase Lz</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase Lz</title>
          <description>Apparent volume of distribution during the terminal phase Lz</description>
          <population>PKS</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" spread="55.1"/>
                    <measurement group_id="O2" value="248" spread="76.3"/>
                    <measurement group_id="O3" value="248" spread="55.5"/>
                    <measurement group_id="O4" value="206" spread="78.0"/>
                    <measurement group_id="O5" value="190" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.</description>
          <population>PKS</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10300" spread="17.5"/>
                    <measurement group_id="O2" value="12100" spread="20.9"/>
                    <measurement group_id="O3" value="12100" spread="24.4"/>
                    <measurement group_id="O4" value="16500" spread="19.9"/>
                    <measurement group_id="O5" value="14900" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)</title>
        <description>Amount of analyte that is eliminated in urine over the time interval 0-96 hours.</description>
        <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)</title>
          <description>Amount of analyte that is eliminated in urine over the time interval 0-96 hours.</description>
          <population>PKS</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17300" spread="26.1"/>
                    <measurement group_id="O2" value="12100" spread="43.8"/>
                    <measurement group_id="O3" value="6840" spread="85.5"/>
                    <measurement group_id="O4" value="3730" spread="49.3"/>
                    <measurement group_id="O5" value="300" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)</title>
        <description>Fraction of analyte excreted unchanged in urine from time point 0-96 hours.</description>
        <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)</title>
          <description>Fraction of analyte excreted unchanged in urine from time point 0-96 hours.</description>
          <population>PKS</population>
          <units>percentage of analyte</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="26.1"/>
                    <measurement group_id="O2" value="10.9" spread="43.8"/>
                    <measurement group_id="O3" value="6.16" spread="85.5"/>
                    <measurement group_id="O4" value="3.36" spread="49.3"/>
                    <measurement group_id="O5" value="0.271" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance of the Analyte in Plasma After Extravascular Administration</title>
        <description>Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.</description>
        <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of the Analyte in Plasma After Extravascular Administration</title>
          <description>Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.</description>
          <population>PKS</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="19.5"/>
                    <measurement group_id="O2" value="16.7" spread="53.7"/>
                    <measurement group_id="O3" value="9.39" spread="87.9"/>
                    <measurement group_id="O4" value="3.70" spread="38.5"/>
                    <measurement group_id="O5" value="0.349" spread="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)</title>
        <description>Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity</description>
        <time_frame>1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)</title>
          <description>Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity</description>
          <population>PKS</population>
          <units>percent</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.869" spread="225"/>
                    <measurement group_id="O2" value="1.07" spread="243"/>
                    <measurement group_id="O3" value="1.21" spread="223"/>
                    <measurement group_id="O4" value="1.78" spread="334"/>
                    <measurement group_id="O5" value="1.14" spread="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Protein Binding</title>
        <description>Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>1 h before drug administration and 1:30 and 3:00 h after drug administration</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Protein Binding</title>
          <description>Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L.
The standard deviation is actually the coefficient of variation.</description>
          <population>PKS</population>
          <units>percentage of plasma protein binding</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.61" spread="1.10"/>
                    <measurement group_id="O2" value="82.72" spread="3.36"/>
                    <measurement group_id="O3" value="81.29" spread="2.48"/>
                    <measurement group_id="O4" value="79.98" spread="2.42"/>
                    <measurement group_id="O5" value="81.08" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:30 h after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.18" spread="1.91"/>
                    <measurement group_id="O2" value="83.70" spread="2.49"/>
                    <measurement group_id="O3" value="82.68" spread="2.76"/>
                    <measurement group_id="O4" value="81.02" spread="1.73"/>
                    <measurement group_id="O5" value="81.09" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 h after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.94" spread="1.88"/>
                    <measurement group_id="O2" value="83.18" spread="2.58"/>
                    <measurement group_id="O3" value="81.90" spread="1.69"/>
                    <measurement group_id="O4" value="80.38" spread="1.61"/>
                    <measurement group_id="O5" value="80.32" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Urinary Glucose Excretion (UGE)</title>
        <description>Change from baseline in total urinary glucose excretion</description>
        <time_frame>24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)</time_frame>
        <population>The UGE analysis set included all patients in the treated set who provided the baseline value from 0 to 24 hours before drug administration and the value for urinary glucose excretion from 0 to 24 hours after drug administration without important protocol violations relevant to the evaluation of Pharmacodynamics.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Urinary Glucose Excretion (UGE)</title>
          <description>Change from baseline in total urinary glucose excretion</description>
          <population>The UGE analysis set included all patients in the treated set who provided the baseline value from 0 to 24 hours before drug administration and the value for urinary glucose excretion from 0 to 24 hours after drug administration without important protocol violations relevant to the evaluation of Pharmacodynamics.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97643" spread="7204"/>
                    <measurement group_id="O2" value="61590" spread="6892"/>
                    <measurement group_id="O3" value="55674" spread="16891"/>
                    <measurement group_id="O4" value="18251" spread="3925"/>
                    <measurement group_id="O5" value="779" spread="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements</title>
        <description>Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements</description>
        <time_frame>Drug administration until end-of-study-examination, 5 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements</title>
          <description>Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical examination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Measurements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Tolerability by Investigator</title>
        <description>Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.</description>
        <time_frame>Drug administration until end-of-study-examination, 5 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Renal Function</title>
            <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Mild Renal Impairment</title>
            <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O3">
            <title>Moderate Renal Impairment</title>
            <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O4">
            <title>Severe Renal Impairment</title>
            <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
          <group group_id="O5">
            <title>Kidney Failure</title>
            <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by Investigator</title>
          <description>Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until end of trial examination, 5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Renal Function</title>
          <description>Patients with type 2 diabetes and normal renal function. Normal renal function was defined as a Glomerular filtration rate of more than 90 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="E2">
          <title>Mild Renal Impairment</title>
          <description>Patients with type 2 diabetes and mild renal impairment. Mild renal impairment was defined as a Glomerular filtration rate of 60-89 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="E3">
          <title>Moderate Renal Impairment</title>
          <description>Patients with type 2 diabetes and moderate renal impairment. Moderate renal impairment was defined as a Glomerular filtration rate of 30-59 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="E4">
          <title>Severe Renal Impairment</title>
          <description>Patients with severe renal impairment. Severe renal impairment was defined as a Glomerular filtration rate of less than 30 mL/min/1.73 m².
Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
        <group group_id="E5">
          <title>Kidney Failure</title>
          <description>Patients with kidney failure, i.e. patients requiring dialysis. Patients were administered once with 50 mg of Empagliflozin as a single dose by oral administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

